Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)’s shares jumped 5.41% to $3.12. The company on Dec. 6 announced new preliminary data from the Phase 2 component of an ongoing Company-sponsored Phase 1/2 trial of TH-302, the Company’s lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib (Velcade®) and low-dose dexamethasone (“TBorD”) for the treatment of patients with relapsed/refractory multiple myeloma (MM). The median number of prior therapies was 8 (range, 4-12). The recommended phase 2 dose of TH-302 was determined to be 340 mg/m2 and no dose limiting toxicities were observed at this dose level. Partial responses (one very good partial response and one partial response) were observed in 2 of 7 (29%) evaluable patients overall and 2 of 4 (50%) evaluable patients at the recommended phase 2 dose of TH-302.

Should Investors Buy THLD After The Recent Development? Find Out Here

Northwest Biotherapeutics, Inc. (NASDAQ:NWBO)’s shares climbed 5.37% to $5.69. The company on Dec. 11 announced that NW Bio’s CEO, Linda Powers, recapped the substantial progress made by the Company during 2014 in a presentation at Oppenheimer’s 25th Annual Healthcare Conference in New York City. The presentation included updates about the DCVax-Direct Phase I trial, including emerging observations about the clinical results, two new case studies (in lung cancer and another type of sarcoma), and plans for the upcoming Phase II trials.  The presentation also included brief updates about the expanding DCVax-L Phase III trial for GBM brain cancer, the early approval programs for DCVax-L in Germany and the UK, and the reimbursement negotiations process in Germany.

Is NWBO Going To Rise or Fall After Today’s Price Action? Find Out Here

BioMarin Pharmaceutical Inc.(NASDAQ:BMRN)’s shares jumped 5.30% to $91.83. The company on Dec. 10 announced that the Agencia Nacional de Vigilancia Sanitaria (ANVISA), or the National Health Surveillance Agency Brazil, has approved VIMIZIM(R) (elosulfase alfa) for the treatment of patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. This is the second country in the month of December to approve VIMIZIM, the first and only treatment for the ultra-rare genetic condition. Australia also approved the therapy on December 7, 2014.

Can Traders Buy BMRN After The Solid Rally? Get Free Trend Analysis Here

About thenextbigtrade.com

thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.

Disclaimer

The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.